Bronson Riley, MS


A 64-Year-Old Man With Germline BRCA2-Mutated Breast Cancer: Known and Unknown Aspects of Male Breast Cancer

This study presents a male breast cancer case with a germline BRCA2 mutation and discusses the epidemiologic, pathologic, and clinical characteristics along with treatment and follow-up recommendations in view of our recent understanding of the disease.

Kirsten Jorgensen, MD


Minimally Invasive Surgery and Laparotomy Yield Similar OS in Ovarian Cancer

Minimally invasive surgery for interval debulking resulted in a lower mortality at the 30- and 90-day time points compared with laparotomy in advanced ovarian cancer.

Khaled W. Kabbara, MD


Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and Therapy

Khaled W. Kabbara, MD, and colleagues, research treatment options for cholangiocarcinoma.

Kristin A. Higgins, MD


Radiotherapy for Oligometastatic Non–Small Cell Lung Cancer: Past, Present, and Future

McCall and Higgins examine local ablative therapy for oligometastatic NSCLC and implications for future treatment of the disease.

Moshe Ornstein, MD, MA


Evolving Treatment Landscape of RCC: Future Directions in Care

Closing out their program on renal cell carcinoma management, key opinion leaders share closing thoughts on emerging therapies and how the field is evolving.

Usama Gergis, MD, MBA


Potential Solutions to Disparities in Stem Cell Transplant for Blood Cancer

Resolving disparities within the blood cancer space is a matter of “access to excellent healthcare,” according to Usama Gergis, MD, MBA.

Ben Kong, PharmD, BCPS


The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint Inhibitors

Ben Kong, PharmD, BCPS, shares a perspective on a study of biomarkers published recently in ONCOLOGY.

Christina Wu, MD


Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer

Investigators discuss the use of targeted therapies to treat metastatic colorectal cancer.

Christina S. Wu, MB, BCh, MD


Tucatinib in Patients With CRC: Data From MOUNTAINEER-01

In the Phase 2 MOUNTAINEER-01 study of patients with HER2-positive metastatic colorectal cancer who were chemo-refractory, the combination of tucatinib and trastuzumab showed an impressive response rate and disease control rate, and median duration of response up to 12 months; Dr. Ahn notes these results compare favorably to prior studies of dual HER2 inhibition, with MOUNTAINEER-01 showing higher response rates.

Zizhen Feng, MD


Combination Therapy With Immune Checkpoint Inhibitors in Urothelial Carcinoma: Current Data and Future Outlook

Until 5 years ago, systemic therapeutic options for urothelial carcinoma, the most common form of bladder cancer, had been limited to cisplatin-based regimens and taxanes. This article explores the current and future outlooks for combination therapy with IOs in urothelial carcinoma.

Reem Akel, MD


Cross Q&A: The Memorial Sloan-Kettering Mavericks

The Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.

Peter Mallmann, MD


Emergency Fertility Preservation in a Young Woman With Non-Hodgkin Lymphoma

A nulliparous woman, age 25 years, had received a diagnosis of non-Hodgkin lymphoma and now presented with stage IIA diffuse large B-cell lymphoma. Due to potential risks of chemotherapy-induced gonadotoxicity and subsequent iatrogenic premature ovarian failure and fertility loss, the patient was referred to the reproductive medicine department for fertility preservation counseling and further management.

Ronan J. Kelly, MD


Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.

Brian Hinds, MD


Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell Carcinoma

In this installment of Clinical Quandaries, Justine Panian, BS, and colleagues present a case of a 60-year-old Mexican woman with fevers, abdominal pain, and hypertension.

Alexey Danilov, MD, PhD


Unmet Needs and Future Perspectives in the Treatment of CLL

The panel shares some final thoughts on unmet needs and the future of CLL treatment.

Eric J. Sherman, MD


Eric J. Sherman, MD, on Agents for Treating RET Fusion–Positive Thyroid Cancer

Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.

Süheyla Aytaç Arslan, MD


Spinal ATRT and Radiotherapy Case Report in an Adult Man

A rare case of spinal atypical teratoid/rhabdoid tumor is presented in an adult man after presenting with neck pain and bilateral upper extremity paralysis.

Timothy Schmidt, MD


Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Deanna Griffie, MSN, AGNP-BC


Unmet Needs in Patient Care for Metastatic Colorectal Cancer

The panel closes by highlighting currently unmet needs in the treatment and management of metastatic colorectal cancer.

Syed Arslan Shehzad Shah, MD


Squamous Cell Carcinoma of the Kidney: A Large Case Series

Syed Arslan Shehzad Shah, MD, and colleagues present findings from a broad investigation into this rare neoplasm of the kidney, including data on patient demographics and mean survival.